stockportfolio.pro
Stocks / PRVA vs RCUS
PRVA vs RCUS
Privia Health Group, Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Privia Health Group, Inc. (PRVA) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $2.9B | $2.8B |
| Revenue (latest FY) | $2.12B | $247.00M |
| Net income (latest FY) | $22.92M | $-353.00M |
| Revenue growth (5y CAGR) | 21.0% | 25.9% |
| Net margin | 1.1% | -142.9% |
| Return on equity | 3.1% | -55.9% |
| P/E ratio | 134.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 1 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PRVA — free Open RCUS — freeFrequently asked questions
Which is bigger, PRVA or RCUS?
Privia Health Group, Inc. is larger by market capitalization — $2.9B versus $2.8B.
Which grows faster, PRVA or RCUS?
Over the last five fiscal years, Arcus Biosciences, Inc. grew revenue faster — 25.9%/yr versus 21.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.